|
Mean (S.D.) Platelet Contractile Force, Clot Elastic Modulus and Thrombin Generation Time at Baseline and Following Increasing Enoxaparin Antifactor Xa Activity |
||||
| Group I |
Group II |
Group III |
||
| Antifactor Xa Activity |
Controls (n = 10) |
Renal Dysfunction (n = 13) |
Diabetes and Renal Dysfunction (n = 7) |
P-value |
|
|
||||
| Baseline |
||||
| PCF† |
8.5 (1.4) |
9.8 (1.5) |
12.0 (2.9)* |
0.003 |
| CEM‡ |
23.2 (5.4) |
29.0 (9.5) |
37.3 (15.5)* |
0.03 |
| TGT§ |
222.0 (60.3) |
235.4 (53.2) |
270.0 (52.0) |
NS |
| 0.25 IU/mL |
||||
| PCF |
7.0 (1.8) |
7.5 (1.6) |
8.8 (2.9) |
NS |
| CEM |
21.1 (4.1) |
22.6 (4.1) |
24.6 (7.1) |
NS |
| TGT |
273.0 (68.5) |
327.7 (70.8) |
325.7 (76.3) |
NS |
| 0.50 IU/mL |
||||
| PCF |
5.5 (1.9) |
5.6 (1.8) |
6.3 (2.4) |
NS |
| CEM |
17.2 (5.1) |
19.1 (4.4) |
19.4 (5.0) |
NS |
| TGT |
318.0 (68.1) |
440.0 (97.5)* |
420.0 (86.6) |
0.007 |
| 1.0 IU/mL |
||||
| PCF |
3.6 (1.7) |
3.0 (1.7) |
4.0 (2.1) |
NS |
| CEM |
11.9 (4.5) |
10.0 (4.6) |
12.9 (6.1) |
NS |
| TGT |
423.0 (128.4) |
588.5 (96.0)* |
552.9 (114.7) |
0.005 |
| 3.0 IU/mL |
||||
| PCF |
1.5 (1.3) |
0.6 (0.2) |
1.0 (0.9) |
0.06 |
| CEM |
4.8 (4.4)* |
0.8 (0.8) |
0.9 (0.8) |
0.003 |
| TGT |
780.0 (317.5) |
1200.0 (0)* |
1200.0 (0)* |
< 0.0001 |
|
† PCF – Kdynes, ‡ CEM – Kdynes/cm2,§TGT – seconds NS – not significant * Statistically significant | ||||
Brophy et al. Thrombosis Journal 2005 3:3 doi:10.1186/1477-9560-3-3 |
||||